Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OREX
If I was a short, I would be covering down here this AM
Yes
I think so.
The last few long term plays have really worked out for me.
CRMMF was a big one for sure. I remember telling you about that one in the .60 range. It got up over $3.00
IMO OREX will go over $10 soon enough
OREX
I bought more this AM at $6.60
Still way up on this one. This is a play that will develop over the next couple of quarters.
I bought more pre-market at $6.60
This is a play for several quarters.
It's a very good bet to gain European approval.
My PT has always been $10
I'm holding all my shares
My PRice target has always been $10
I'm holding
Typical short squeeze
It's about time
Big volume
Awesome
I'm still in both OREX and MEIP
Something's gotta give
I still have all of my shares.
Waiting for the run
They have managed to really walk this down over the past 2 sessions.
IMO we should be in for a nice bounce.
I just doubled down at 23.80
What's the feeling here on MEIP?
Price of oil trending up this AM
New here.
Got in recently under 25
Looks like it could have wheels?
Yes
I'm not sure why.
It's obviously undervalued at these levels
Great news
CC starting now.
OREX
Conf call in 18 minutes!
Great Contrave sales during 4th Q launch!
Jumped back in here pre-market just now.
Orexigen's partner for North America, Takeda Pharmaceuticals, launched Contrave in the United States on October 20, 2014. U.S. net sales for the fourth quarter, recorded by Takeda, were $6.5 million, for which Orexigen earned $1.3 million in royalties. Gross sales for the quarter were $12.3 million.
As of December 31, 2014, Orexigen had $104.2 million in cash and cash equivalents and an additional $101.3 million in marketable securities, for a total of $205.5 million.
Conference Call Today at 7:30 a.m. Eastern Time (4:30 a.m. Pacific Time)
OREX
Orexigen's partner for North America, Takeda Pharmaceuticals, launched Contrave in the United States on October 20, 2014. U.S. net sales for the fourth quarter, recorded by Takeda, were $6.5 million, for which Orexigen earned $1.3 million in royalties. Gross sales for the quarter were $12.3 million.
As of December 31, 2014, Orexigen had $104.2 million in cash and cash equivalents and an additional $101.3 million in marketable securities, for a total of $205.5 million.
Conference Call Today at 7:30 a.m. Eastern Time (4:30 a.m. Pacific Time)
Me too
weaker hands are bailing and taking profits.
I'm a buyer down here.
IMO, we get good news tomorrow.
Price targets from the "pros" are encouraging.
OREX & MEIP
I just bought the dip on both of these!
I sure hope so
OREX
The Contrave launch has been a huge success.
IMO we should see the share price climb today in anticipation of good news tomorrow morning.
The Contrave launch has been a huge success.
IMO we should see the share price climb today in anticipation of good news tomorrow morning.
I think so.
Folks sold early taking profits and new $ coming in.
Shorts should cover before Wednesday
IMO
I bought the dip at 5.77
This is just folks taking profits and re-accumulation
She bounces back to $6.08 by EOD IMHO
OREX
It was a very successful launch by all accounts.
Sales numbers should beat!
IMHO this will fly this week
Good move
Enjoying the ride here.
I just bought another large block on the dip this morning.
Looking forward to Wednesday
Out ore-market at 30.96
That's just SOP for them.
Should be a fun week for us here
Jumped in here again pre-market at 30.81
I'll ride it for a couple of days
I'm holding all and would like to add some if I can.
The Contrave launch has been a huge success so I'm banking on a nice earnings report.
IMO of course.
OREX
SAN DIEGO, Feb. 20, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX) will announce financial results for the fourth quarter and full year 2014 on Wednesday, February 25 before the market opens. The announcement will be followed by a live webcast and conference call at 7:30 a.m. Eastern Time (4:30 a.m. Pacific Time).
The live call may be accessed by phone by calling (800) 708-4540 (domestic) or (847) 619-6397 (international), participant code 39030980. The webcast can be accessed live on the Investors section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.
Orexigen Contact:
McDavid Stilwell, Vice President, Corporate Communications and Business Development
(858) 875-8629
Media Contact:
David Walsey, BrewLife
(858) 617-0772
OREX
SAN DIEGO, Feb. 20, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX) will announce financial results for the fourth quarter and full year 2014 on Wednesday, February 25 before the market opens. The announcement will be followed by a live webcast and conference call at 7:30 a.m. Eastern Time (4:30 a.m. Pacific Time).
The live call may be accessed by phone by calling (800) 708-4540 (domestic) or (847) 619-6397 (international), participant code 39030980. The webcast can be accessed live on the Investors section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.
Orexigen Contact:
McDavid Stilwell, Vice President, Corporate Communications and Business Development
(858) 875-8629
Media Contact:
David Walsey, BrewLife
(858) 617-0772